Neubase Therapeutics Inc Quick Ratio (NBSE) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Neubase Therapeutics inc   (NASDAQ: NBSE)

Neubase Therapeutics Inc 's Quick Ratio

NBSE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Neubase Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Neubase Therapeutics Inc 's Quick Ratio to 2.73, Quick Ratio remained below Neubase Therapeutics inc average.

Within Major Pharmaceutical Preparations industry 320 other companies have achieved higher Quick Ratio than Neubase Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 1475, from total ranking in the second quarter 2023 at 1686.

Explain Quick Ratio?
How much Cash & cash equivalents NBSE´s has?
What are NBSE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBSE Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q1		 (Sep 30 2022)
Q4
Y / Y Current Liabilities Change 11.61 % 73.73 % -61.48 % -40.52 % -0.66 %
Y / Y Cash & cash equivalent Change -45.8 % -50.62 % -64.07 % -62.88 % -55.92 %
Quick Ratio MRQ 2.73 2.43 7.34 8.23 5.62
NBSE's Total Ranking # 1475 # 1686 # 783 # 800 # 1119
Seq. Current Liabilities Change -24.06 % 218.91 % -10.5 % -48.51 % 18.21 %
Seq. Cash & cash equivalent Change -14.64 % 5.51 % -20.18 % -24.62 % -22.22 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 321
Healthcare Sector # 560
Overall Market # 1436


Quick Ratio Statistics
High Average Low
36.87 7.88 0.08
(Jun 30 2014)   (Sep 30 2011)




Financial Statements
Neubase Therapeutics Inc 's Current Liabilities $ 5 Millions Visit NBSE's Balance sheet
Neubase Therapeutics Inc 's Cash & cash equivalent $ 13 Millions Visit NBSE's Balance sheet
Source of NBSE's Sales Visit NBSE's Sales by Geography


Cumulative Neubase Therapeutics Inc 's Quick Ratio

NBSE's Quick Ratio for the trailling 12 Months

NBSE Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -8.87 % -11.99 % -26.18 % 4.03 % 20.03 %
Y / Y Cash & cash equivalent TTM Growth -57.73 % -58.81 % -57.15 % -40.09 % -16.94 %
Quick Ratio TTM 4 4.88 7.26 7.45 8.62
Total Ranking TTM # 4020 # 3802 # 3652 # 33 # 2938
Seq. Current Liabilities TTM Growth 3.37 % 22.1 % -20.68 % -8.97 % -0.17 %
Seq. Cash & cash equivalent TTM Growth -15.32 % -17.87 % -22.76 % -21.32 % -17.47 %

Quick ratio ranking by company, industry and sector >> Back to NBSE Financial Strength Comparisons >> Go to Compare NBSE Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q3 2023 to $4.65 millions, cumulative Quick Ratio decreased to 4 below the Neubase Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 536 other companies have achieved higher Quick Ratio than Neubase Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3802 to 4020.

Explain Quick Ratio?
How much Cash & cash equivalents NBSE´s has?
What are NBSE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 537
Healthcare Sector # 1076
Within the Market # 4020


trailing twelve months Quick Ratio Statistics
High Average Low
13.61 5.96 2.13
(Jun 30 2021)   (Dec 31 2014)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Hoth Therapeutics Inc   7.51 $ 11.853  Millions$ 1.579  Millions
Applied Molecular Transport Inc   7.47 $ 18.103  Millions$ 2.422  Millions
Rein Therapeutics Inc   7.43 $ 12.069  Millions$ 1.624  Millions
Ngm Biopharmaceuticals Inc   7.43 $ 166.045  Millions$ 22.345  Millions
Verrica Pharmaceuticals Inc   7.41 $ 84.308  Millions$ 11.374  Millions
Nanoviricides inc   7.35 $ 6.970  Millions$ 0.948  Millions
Merus N v   7.32 $ 471.029  Millions$ 64.318  Millions
Kronos Bio Inc   7.27 $ 186.713  Millions$ 25.672  Millions
Carisma Therapeutics Inc   7.27 $ 94.137  Millions$ 12.951  Millions
Vera Therapeutics Inc   7.24 $ 159.939  Millions$ 22.103  Millions
Dermata Therapeutics Inc   7.23 $ 6.631  Millions$ 0.917  Millions
Shattuck Labs Inc   7.19 $ 101.074  Millions$ 14.059  Millions
Nektar Therapeutics  7.15 $ 372.658  Millions$ 52.112  Millions
Abcellera Biologics Inc   7.13 $ 785.840  Millions$ 110.239  Millions
Lumos Pharma Inc   7.13 $ 42.694  Millions$ 5.990  Millions
Mirati Therapeutics Inc   7.11 $ 976.434  Millions$ 137.379  Millions
Matinas Biopharma Holdings Inc   7.03 $ 18.216  Millions$ 2.592  Millions
Verastem Inc   6.96 $ 165.663  Millions$ 23.812  Millions
Sage Therapeutics Inc   6.95 $ 876.052  Millions$ 126.037  Millions
Immix Biopharma Inc   6.93 $ 19.582  Millions$ 2.826  Millions
Rain Enhancement Technologies Holdco Inc   6.93 $ 77.320  Millions$ 11.163  Millions
Lexicon Pharmaceuticals Inc   6.77 $ 218.427  Millions$ 32.261  Millions
Mira Pharmaceuticals Inc   6.76 $ 5.868  Millions$ 0.868  Millions
Enlivex Therapeutics Ltd  6.72 $ 32.428  Millions$ 4.828  Millions
Assembly Biosciences Inc   6.48 $ 46.210  Millions$ 7.132  Millions
Abeona Therapeutics Inc   6.39 $ 53.754  Millions$ 8.412  Millions
Bolt Biotherapeutics Inc   6.38 $ 119.724  Millions$ 18.751  Millions
Mineralys Therapeutics Inc   6.37 $ 86.300  Millions$ 13.543  Millions
Clearmind Medicine Inc  6.34 $ 3.911  Millions$ 0.617  Millions
Moleculin Biotech Inc   6.32 $ 24.579  Millions$ 3.888  Millions

Date modified: 2026-09-08T15:22:12+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.